Thank you for subscribing!
Next Investors Feb 18, 2022
Today we are finally announcing a new investment in the Next Investors portfolio. Arovella Therapeutics (ASX:ALA) is a small ASX biotech going after a unique solution to the scourge of cancer - with cutting edge technology licensed from some of the foremost cancer research institutions - and has attracted big names to the project.
Finfeed Feb 01, 2022
Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.
Next Investors Aug 16, 2021
Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.
Next Investors Archived Jun 19, 2020
Backed by a new leadership team, ASX-listed biotech junior, eSense-Lab (ASX:ESE) is implementing a new business model that sees it enter joint venture (JV) agreements to quickly reach multiple revenue-generating markets.
Get expert stock analysis direct in your inbox
Finfeed Archived Jun 15, 2020
eSense-Lab Limited (ASX: ESE) has entered a JV with ANC Enterprises to provide specific terpenes uniquely developed for a range of skin care, hair care and hand sanitiser products. ANC will formulate and manufacture the resulting products containing ESE’s proprietary terpene mixes.
Finfeed Archived May 22, 2020
Genetic Technologies (ASX: GTG | NASDAQ: GENE) is fast-tracking development of a genetic test that will determine if people are at a high risk of contracting COVID-19.
Finfeed Archived May 11, 2020
There has been continual strong news flow from the Genetic Signature Ltd (ASX: GSS), as it received CE-IVD registration for its SARS-CoV-2 Detection Kit, as well as notification from the Therapeutic Goods Administration (TGA) that its EasyScreenTM SARS-CoV-2 Detection Kit has been approved to be listed on the ARTG in Australia.
Next Investors Archived May 05, 2020
OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.
Finfeed Archived Apr 16, 2020
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, has secured CE Mark registration for its PromarkerD Immunoassay kit as an IVD medical device (in vitro diagnostic).
Join Our Mailing List
